After Blockbuster Phase 3 Results in Surgical Infection Prevention, This $35M Israeli Innovator Could Become Big Pharma’s Most Coveted Acquisition Target In the frenzy surrounding GLP-1 weight loss medications, one…
Posts published in “Wall Street Wire”
Company demonstrates rapid weight loss in animal models with potential best-in-class oral MC4R therapy Palatin Technologies (OTCQB: PTNT) (NYSE: PTN) has just released compelling preclinical efficacy data for PL7737, its…
Under the Radar Phage Therapy Trailblazer Begins Next Chapter in Fight Against Antibiotic-Resistant Infections BiomX (NYSE: PHGE) just announced that is successfully completed the first patient dosing in its Phase…
New study reveals Nuvectis Pharma’s NXP900 to be safe to use with CYP3A, the enzyme pathway through which many leading NSCLC therapies are metabolized; NXP900 could be come the ideal…
Wall Street Analysts Think PolyPid, a $35M BioPharma Player is Significantly Undervalued, Here’s Why
Wall Street Analysts Think PolyPid, a $35M BioPharma Player is Significantly Undervalued, Here’s Why
In the competitive landscape of biotechnology investments, discovering undervalued opportunities with significant upside potential requires careful analysis of clinical milestones, market positioning, and Wall Street sentiment. PolyPid Ltd. (NASDAQ: PYPD),…
Imagine a world where managing multiple chronic conditions isn’t a nightmare of fragmented care, endless appointments, and mounting medical bills. This isn’t a futuristic fantasy, it’s the vision of DarioHealth…
Surgical infection prevention breakthrough demonstrates 58% infection reduction as company secures funding through regulatory approval PolyPid Ltd. (NASDAQ: PYPD)* announced Tuesday that it has secured $26.7 million through warrant exercises…
Rumours have swirled for months about a new drone quietly used in Israel’s most volatile flash‑points—small enough to launch from a backpack, yet lethal enough to end a firefight with…
For 90 seconds on a late April morning, one of the busiest airports in America went dark. Air traffic controllers at Newark Liberty International Airport lost radar and radio contact…
Breakthrough Phase 3 topline data released today shows 58% reduction in surgical infections as analysts maintain $11-$13 price targets on $2.89 stock PolyPid Ltd. (NASDAQ: PYPD)* just announced results that…